Analyst Research
| Report Title | Price |
|---|---|
|
Provider: Thomson Reuters Stock Report
|
$25.00
|
|
Provider: GlobalData
|
$250.00
|
|
Provider: Pechala's Reports
|
$15.00
|
|
Provider: Reuters Investment Profile
|
$20.00
|
NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
Angiodynamics Inc Reiterates FY 2013 Guidance-Conference Call
Angiodynamics Inc reiterated the guidance that laid out in fourth-quarter earnings conference call unchanged. The Company believes topline will grow 5% in fiscal 2013 from the pro forma last year and will exit the year with a high single-digit rate of growth of revenues, Operating income $34 million to $36 million on a non-GAAP basis and excluding all of the acquisition effects of course. According to I/B/E/S Estimates, analysts are expecting the Company to report revenue of $360 million, and operating profit of $34 million for fiscal 2013.
Latest Developments for AngioDynamics Inc
- Angiodynamics Inc Lowers FY 2013 Guidance
- Angiodynamics Inc Issues Q3 2013 Guidance Below Analysts' Estimates
- Angiodynamics Inc Sees FY 2013 Revenue Guidance To A Slightly Lower Midpoint Of Prior Range; Reaffirms FY 2013 EPS Guidance-Conference Call
- Angiodynamics Inc Reaffirms FY 2013 Guidance; Lowers FY 2013 Revenue And EBITDA Guidance
Latest Key Developments in Medical
- Share this
- Link this
- Digg this


Follow Reuters